The Manufacturers Life Insurance Company Takes Position in Disc Medicine, Inc. $IRON

The Manufacturers Life Insurance Company acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 27,771 shares of the company's stock, valued at approximately $2,031,000. The Manufacturers Life Insurance Company owned approximately 0.73% of Disc Medicine as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Disc Medicine during the second quarter worth $180,502,000. JPMorgan Chase & Co. boosted its position in shares of Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after purchasing an additional 828,248 shares during the period. BVF Inc. IL acquired a new position in shares of Disc Medicine in the 4th quarter valued at $51,616,000. Perceptive Advisors LLC purchased a new position in Disc Medicine in the 4th quarter worth about $35,794,000. Finally, RA Capital Management L.P. increased its stake in Disc Medicine by 25.3% in the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after purchasing an additional 399,026 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Trading Up 1.8%

Shares of NASDAQ IRON opened at $80.05 on Thursday. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The firm has a market capitalization of $3.07 billion, a PE ratio of -12.17 and a beta of 0.98. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $77.49 and a two-hundred day moving average price of $70.15.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17. As a group, analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 34,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total value of $2,387,140.00. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at $15,871,953.44. This represents a 13.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the sale, the insider directly owned 52,173 shares of the company's stock, valued at $3,663,588.06. This trade represents a 12.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 153,612 shares of company stock valued at $11,431,811. Corporate insiders own 3.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IRON shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Disc Medicine in a research note on Tuesday. HC Wainwright boosted their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Disc Medicine from a "hold" rating to a "sell" rating in a report on Saturday, August 29th. Morgan Stanley restated an "overweight" rating and issued a $90.00 price target on shares of Disc Medicine in a research report on Monday, August 17th. Finally, Wedbush raised their price objective on shares of Disc Medicine from $88.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of "Moderate Buy" and a consensus price target of $107.70.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source